Clinical trials: Olaparib, completed
Ovarian Cancer
Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who harbour a germline mutation…
- Trial name
- MOLTO (NCT02855697)
- Testing
- Olaparib, Cediranib, Platinum-based Chemotherapy
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- The Christie NHS Foundation Trust
Ovarian Cancer, Breast Cancer
A Study of Serum Folate Levels in Patients Treated With Olaparib
This is a study investigating folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib to treat their advanced ovarian or breast cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Folic Acid Deficiency
- Trial name
- NCT04024254
- Testing
- Folic Acid Tablet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Brain and Central Nervous System Tumors
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01390571
- Testing
- olaparib, temozolomide, gene expression analysis
- Where
- 7 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Cancer Research UK
Neoplasms
Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
This study aimed to evaluate the pharmacokinetic characteristics and bioequivalence of two olaparib tablets in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Trial name
- NCT05860530
- Testing
- The test olaparib tablet (T), The reference olaparib tablet (R)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Neoplasms, Germ Cell and Embryonal
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
This is open-label, single-arm, two-stage phase II trial of olaparib in patients with relapsed/refractory metastatic germ cell cancer. The primary objective is to evaluate the preliminary activity of Olaparib in GCT tumors.
- Trial name
- NCT02533765
- Testing
- Olaparib
- Where
- 2 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recurrent IDH, Mutant High Grade Glioma
Olaparib in Recurrent IDH-mutant Glioma
Recent data demonstrate that in IDH-mutant gliomas, 2 hydroxy-glutarate production induces a homologous recombination defect that renders tumor cells exquisitely sensitive to poly(adenosine 5'-diphosphate-ribose) polymerase…
- Trial name
- OLAGLI (NCT03561870)
- Testing
- Olaparib 150 MG
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Hospices Civils de Lyon
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
- Conditions
- Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
- Trial name
- NCT00516724
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Carboplatin, Paclitaxel
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 189 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Metastatic
SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients
Open label multicentric randomized phase II trial, using high throughput genome analysis as a therapeutic decision tool, aimed at comparing a targeted treatment administered according to the identified molecular anomalies of the…
- Trial name
- SAFIR02_Lung (NCT02117167)
- Testing
- AZD2014, AZD4547, AZD5363
- Where
- 37 sites in France
- Volunteers
- 999 people
- Sponsor
- UNICANCER
Non-Germline BRCA Mutated Ovarian Cancer
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or…
- Trial name
- OPINION (NCT03402841)
- Testing
- Olaparib
- Where
- 91 sites in Austria, Belgium and 17 more
- Volunteers
- 279 people
- Sponsor
- AstraZeneca
Ovarian Neoplasms, BRCA1 Protein
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours.
- Conditions
- Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein
- Trial name
- NCT00516373
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor)
- Where
- 5 sites in Belgium, Netherlands and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Solid Tumor
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
This research study is studying a combination of targeted therapies as a possible treatment for Advanced Solid Tumors. The study interventions involved in this study are: LY2606368 Olaparib
- Trial name
- NCT03057145
- Testing
- Prexasertib, Olaparib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Geoffrey Shapiro, MD, PhD
Endometrial Cancer
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
This is a window study where treatment-naïve patients will receive olaparib before definitive treatment. The aim is to evaluate the DNA damage and inflammatory response after PARP inhibitor.
- Trial name
- NCT05320757
- Testing
- Olaparib
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Pancreatic Neoplasms
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
- Trial name
- NCT00515866
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 68 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Advanced Solid Tumors
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
- Trial name
- NCT05240898
- Testing
- RO7623066, Olaparib, Carboplatin
- Where
- 15 sites in United States
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Arterial Hypertension Related to PARP Inhibitors (ArteRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but serious (or not) adverse events such as hypertension whose data are scarce.
- Trial name
- NCT04774406
- Testing
- olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
- Where
- France
- Volunteers
- 2,336 people
- Sponsor
- University Hospital, Caen
Ovarian Cancer
Platine, Avastin and OLAparib in 1st Line
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line…
- Trial name
- PAOLA-1 (NCT02477644)
- Testing
- Olaparib
- Where
- 163 sites in Austria, Belgium and 9 more
- Volunteers
- 806 people
- Sponsor
- Arcagy Research
Soft Tissue Sarcoma
Molecular Profiling of Advanced Soft-tissue Sarcomas
MULTISARC is a randomized multicenter study assessing whether high throughput molecular analysis (next generation sequencing exome - NGS) is feasible in advanced/metastatic soft-tissue sarcoma patients, that is, whether NGS can…
- Trial name
- MULTISARC (NCT03784014)
- Testing
- Nilotinib, Ceritinib, Capmatinib
- Where
- 17 sites in France
- Volunteers
- 603 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ovarian, Breast
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
- Conditions
- Ovarian, Breast, Prostate, Pancreatic
- Trial name
- NCT01078662
- Testing
- olaparib
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 298 people
- Sponsor
- AstraZeneca